# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2019 Earnings Results

**Report date:** 2019-08-06 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2019

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.23%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.02 | N/A | +12.13% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook based on current product performance. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> Management highlighted the strong performance of their key products.

> They expressed confidence in their ongoing research and development efforts.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported a better-than-expected EPS, which contributed to a slight increase in the stock price by 0.23%. The company did not disclose revenue figures or future guidance, leaving investors with limited insights on long-term performance. The positive EPS surprise suggests that the company is managing its costs effectively and performing well in its core areas.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2019_